RxSight, Inc.
RXST
$6.26
-$0.23-3.54%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 32.61M | 30.34M | 33.64M | 37.90M | 40.21M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 32.61M | 30.34M | 33.64M | 37.90M | 40.21M |
| Cost of Revenue | 7.35M | 6.11M | 8.45M | 9.57M | 11.43M |
| Gross Profit | 25.26M | 24.23M | 25.19M | 28.33M | 28.79M |
| SG&A Expenses | 27.70M | 27.35M | 28.98M | 28.64M | 28.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.95M | 42.52M | 47.64M | 48.57M | 48.84M |
| Operating Income | -11.34M | -12.18M | -14.00M | -10.67M | -8.63M |
| Income Before Tax | -9.15M | -9.81M | -11.75M | -8.17M | -5.93M |
| Income Tax Expenses | 5.00K | 10.00K | 32.00K | 18.00K | 12.00K |
| Earnings from Continuing Operations | -9.15M | -9.82M | -11.79M | -8.19M | -5.94M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.15M | -9.82M | -11.79M | -8.19M | -5.94M |
| EBIT | -11.34M | -12.18M | -14.00M | -10.67M | -8.63M |
| EBITDA | -10.49M | -11.32M | -13.22M | -9.90M | -8.11M |
| EPS Basic | -0.22 | -0.24 | -0.29 | -0.20 | -0.15 |
| Normalized Basic EPS | -0.14 | -0.15 | -0.18 | -0.13 | -0.09 |
| EPS Diluted | -0.22 | -0.24 | -0.29 | -0.20 | -0.15 |
| Normalized Diluted EPS | -0.14 | -0.15 | -0.18 | -0.13 | -0.09 |
| Average Basic Shares Outstanding | 41.18M | 40.97M | 40.74M | 40.51M | 40.36M |
| Average Diluted Shares Outstanding | 41.18M | 40.97M | 40.74M | 40.51M | 40.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |